(Sharecast News) - German biotechnology company BioNTech announced the $800m acquisition of Chinese biotech firm Biotheus on Wednesday, in a bid to further strengthen its oncology pipeline.
The acquisition would grant BioNTech full global rights to the promising bispecific antibody BNT327/PM8002, which was designed to target both PD-L1 and VEGF-A in...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE